KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
KNTE
Delisted
KNTE was delisted on the 2nd of April, 2024.
71 hedge funds and large institutions have $750M invested in Kinnate Biopharma Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 14 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
71
Holders Change
-2
Holders Change %
-2.74%
% of All Funds
1.1%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.08%
New
10
Increased
25
Reduced
14
Closed
12
Calls
–
Puts
$23K
Net Calls
-$23K
Net Calls Change
-$23K
Top Buyers
| 1 |
N
Natixis
Paris,
France
|
$11.9M |
| 2 |
BlackRock
New York
|
$36.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
$34.1M |
| 4 |
State Street
Boston,
Massachusetts
|
$6.89M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
$9.8M |
Top Sellers
| 1 |
VA
VR Adviser
New York
|
$13.7M |
| 2 |
Morgan Stanley
New York
|
$631K |
| 3 |
Millennium Management
New York
|
$0 |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
$0 |
| 5 |
DM
Deerfield Management
New York
|
$17.5M |
